You are here: Home » Companies » News
Business Standard

India biz may stabilise in FY19, but govt price caps a concern: Sun Pharma

The company's India business revenues stood at Rs 80.29 billion in 2017-18, a growth of 4 per cent over 2016-17

Press Trust of India  |  New Delhi 

Sun Pharma
FILE PHOTO: A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai | Photo: Reuters

expects its India business to stabilise in the current fiscal leading to "reasonable volume growth" after witnessing disruptions in 2017-18 due to implementation, a top company official said.

In a message to shareholders in the company's Annual Report for 2017-18, Managing Director Dilip Shanghvi, however, said the government's enforced price cuts and policy changes are potential risk factors for the business.

"We expect normalisation of the India business in 2018-19 post the disruption in 2017-18 due to implementation. Favourable demographics will ensure reasonable volume growth in India," Shanghvi said.

However, government-mandated price reductions/policy changes continue to be potential risks for this business, he added.

The company's India business revenues stood at Rs 80.29 billion in 2017-18, a growth of 4 per cent over 2016-17.

Shanghvi said the short-term outlook for the US generics market continues to be challenging given the pricing pressures.

"We are also expecting reasonable growth in our emerging markets business, however, as always, currency fluctuations continue to be a risk," he added.

Elaborating further, he said the company is in the process of gradually ramping up its global specialty business.

"We plan to increase its contribution to our consolidated revenues in the long term. This will entail significant front-ended investments, with commensurate revenue streams accruing only over a period of time," Shanghvi said.

ALSO READ: Sun Pharma looks to grow complex generics, specialty products biz faster

Some of the company's specialty products are likely to be commercialised in the US in 2018-19 and hence it expects to incur significant pre-launch and branding costs along with increasing sales force costs, he added.

"Given these factors, we expect a low double-digit topline growth in our consolidated revenues for 2018-19 over 2017-18," Shanghvi said.

The Mumbai-based drug firm posted consolidated revenues of Rs 264.89 crore for 2017-18.

Shanghvi said the company's consolidated R&D investments for 2018-19 will be about 8-9 per cent of its revenues.

First Published: Tue, October 02 2018. 17:10 IST